Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
MANNITOL
Renal · Renal · Level 3
|
FRUSEMIDE
Renal · Renal · Level 1
|
HYDROCHLOROTHIAZIDE
Renal · Renal · Level 3
|
SPIRONOLACTONE
Renal · Renal · Level 3
|
|---|---|---|---|---|
| Mechanism of action | Freely filtered at the glomerulus and not reabsorbed. It increases tubular-fluid osmolality and urine volume. Because it does not cross an intact blood-brain barrier, it also draws extracellular water from brain into plasma and reduces CSF volume and pressure. osmotic agent. inc plasma osmolality and draws water out of the CSF and vitreous body. Freely fi¬ltered at the glomerulus but poorly reabsorbed. Because • increases the osmolarity of the glomerular |
Diuresis |
inhibit Na+ reabsorption in the early portion of the distal tubule by |
Acts in the DCT. |
| Physiological effects | ↓ICP/IOP |
Pulmonary and systemic vasodilation |
Anti-HTN: (↓TPR, ↓plasma volume) |
Sedation and muscle weakness (due to electrolyte abnm) |
| Absorption | IV only. |
PO/IV/SL/IM. PO BA 50% Onset PO/SL 30-60mins, IV 5 mins . |
PO- BA ~50-80%. Onset 2hrs Dur 6-12hrs. |
PO - BA 70%, extensive 1st pass metb. Onset 3-4hrs, dur upto 3 days |
| Distribution | Biphasic – plasma and ECF. |
— | — | — |
| Protein binding | — | 91-99% (Albumin) |
68% |
90% |
| Volume of distribution | 0.47 L/kg |
0.1L/kg |
3.6-7.8L/kg |
— |
| Metabolism | Not metabolised to a clinically significant extent. Excreted unchanged in urine. Minimally hepatic to glycogen Unmetabolized |
Renal to glucuronide |
Not metabolized |
Hepatic: Rapidly and extensively metabolised by deacetylation and dethiolation. Active metab: canrenone and 7-alpha-spirolactone |
| Excretion | Urine (~55% to 87% as unchanged drug) |
80% unchanged in urine |
Urine (unchanged) |
Urine and faeces |
| Half-life | Term half life: 4.7 hrs |
0.5-2hrs. ESRF: 9hrs |
5.6-14.8hrs |
1-2hours, metab upto 24hrs |
| Adverse Effects Toxicity | Usually rare and idosyncratic. It may cause symptoms of pulmonary hypertension. |
↓ K+/Na+/Cl-/Ca++, Hyper- urea/glu/chol, Metabolic alkalosis |
↓K+/Na+/Mg++, ↑Ca++/urea/glu/chol. |
↑K+(esp in renal failure). N/V and GI disturbances |
| Class Group | Osmotic Diuretic Diuretic - Osmotic |
Diuretic - Loop |
Diuretic - Thiazide |
Diuretic – Aldosterone antagonist |
| Indications Uses | Used to reduce CSF pressure and volume, for short-term management of acute glaucoma, as an osmotic diuretic in selected renal indications, for bowel preparation and in rhabdomyolysis. osmotic diuretic 1. reduce CSF volume -> reduce ICP |
Oedema of cardiac, renal or hepatic origin, Renal insufficency |
heart failure and hypertension. Used in combination. mostly bound to plasma prot, and gain access to the tubule via secretion in the PCT. |
Oedema – CHF, cirrhosis with ascites, refractory. HTN, Nephrotic syndrome. With loop/thiazide to conserve K+, diagn of Conn's syndr |
| Introduction | Mannitol is a low-molecular-weight polyol (molecular weight 182) used as an osmotic agent. polyhydric alcohol MW 200, synthesized by redn of mannose an alcohol derived from Dahila tubers (6 carbon decrease ICP: 0.25g/kg over 15min to 1g/kg PROS & CONS – See BELOW |
Sulfonamide derivative |
related to the sulphonamides |
A synthetic steroid |
| Legacy Cicm Level | Level 3 |
Level 1 |
Level 3 |
Level 3 |
| Presentation | Sterile 10% and 20% aqueous solutions. Crystallisation may occur at low temperatures. 1-% or 20% (100gm in 1000ml or 500ml) sterile solution |
Photosensitive solution 10mg/ml |
orange scored tablets of 25mg and combos |
25/100mg tablets |
| Route And Dose | 1-2gm/kg IV |
20-2000mg daily |
PO. 12.5-200mg/day |
PO. 25-200mg/day |
| Special Points | Osm (20%) 1100 ADVANTAGES: DISADVANTAGES: |
— | — | — |